Published in Iran J Pharm Res on January 01, 2015
Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative. Pharmaceutics (2017) 0.75
A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol (2001) 4.39
The anthracyclines: will we ever find a better doxorubicin? Semin Oncol (1992) 3.28
Anthracyclines in the treatment of cancer. An overview. Drugs (1997) 2.36
Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem (2009) 1.95
The rise of the mouse, biomedicine's model mammal. Science (2000) 1.72
The liposomal formulation of doxorubicin. Methods Enzymol (2005) 1.62
Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release (2001) 1.39
Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.99
Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1998) 0.96
A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine (2011) 0.92
Reduction of animal usage by serial bleeding of mice for pharmacokinetic studies: application of robotic sample preparation and fast liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl (2001) 0.91
High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. J Chromatogr B Biomed Sci Appl (1999) 0.87
A validated assay for measuring doxorubicin in biological fluids and tissues in an isolated lung perfusion model: matrix effect and heparin interference strongly influence doxorubicin measurements. J Pharm Biomed Anal (2003) 0.86
Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.86
Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity. Int J Pharm (2006) 0.85
Solid-phase extraction and optimized separation of doxorubicin, epirubicin and their metabolites using reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal (1993) 0.85
HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.85
Biocompatible microemulsion modifies the pharmacokinetic profile and cardiotoxicity of doxorubicin. J Pharm Sci (2012) 0.84
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). Oncol Rep (2004) 0.84
Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem (1999) 0.84
A simple and rapid high performance liquid chromatography method to determine levofloxacin in human plasma and its use in a bioequivalence study. Drug Discov Ther (2007) 0.83
Improved HPLC method for doxorubicin quantification in rat plasma to study the pharmacokinetics of micelle-encapsulated and liposome-encapsulated doxorubicin formulations. Biomed Chromatogr (2008) 0.82
A simple HPLC method for doxorubicin in plasma and tissues of nude mice. Arch Pharm Res (2009) 0.82
Development and Validation of a Reversed-phase HPLC Method for Assay of the Decapeptide Cetrorelix Acetate in Bulk and Pharmaceutical Dosage Forms. Iran J Pharm Res (2014) 0.82
Selective determination of doxorubicin and doxorubicinol in rat plasma by HPLC with photosensitization reaction followed by chemiluminescence detection. Talanta (2008) 0.81
Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.80
A Rapid and Sensitive HPLC-Fluorescence Method for Determination of Mirtazapine and Its two Major Metabolites in Human Plasma. Iran J Pharm Res (2014) 0.79
In vivo sampling for pharmacokinetic studies in small experimental animals: a combination of microdialysis, planar chromatography and digital autoradiography. Mol Imaging Biol (2004) 0.79
Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice. J Pharm Sci (2009) 0.79
Simultaneous determination of epirubicin, doxorubicin and their principal metabolites in human plasma by high-performance liquid chromatography and electrochemical detection. J Chromatogr B Biomed Sci Appl (1998) 0.79
A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach. Crit Rev Ther Drug Carrier Syst (2013) 0.79
Simultaneous quantitation of plasma doxorubicin and prochlorperazine content by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1997) 0.78
Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin. Arch Pharm Res (2011) 0.78
Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients. J Chromatogr B Analyt Technol Biomed Life Sci (2014) 0.78
High performance liquid chromatographic determination of some co-administered anticancer drugs in pharmaceutical preparations and in spiked human plasma. J Pharm Biomed Anal (2004) 0.77
Deposition of doxorubicin in rats following administration of three newly synthesized doxorubicin conjugates. Biomed Res Int (2013) 0.77
Development of an analytical methodology for simultaneous determination of vincristine and doxorubicin in pharmaceutical preparations for oncology by HPLC-UV. J Chromatogr Sci (2009) 0.77
Preparation and characterization of stable nanoliposomal formulation of fluoxetine as a potential adjuvant therapy for drug-resistant tumors. Iran J Pharm Res (2014) 0.87
Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: a comparison of phospholipid micelles and liposomes. Int J Pharm (2013) 0.83
Chitosan gel-embedded moxifloxacin niosomes: An efficient antimicrobial hybrid system for burn infection. Int J Biol Macromol (2016) 0.76
Metabolite parameters as an appropriate alternative approach for assessment of bioequivalence of two verapamil formulations. Iran J Pharm Res (2014) 0.75
Doxorubicin-loaded liposomes: enhancing the oral bioavailability by modulation of physicochemical characteristics. Nanomedicine (Lond) (2017) 0.75
Effective attenuation of vascular restenosis following local delivery of chitosan decorated sirolimus liposomes. Carbohydr Polym (2016) 0.75
Utilization of chitosan-caged liposomes to push the boundaries of therapeutic delivery. Carbohydr Polym (2016) 0.75
Physicochemical characteristics of liposomes are decisive for their antirestenosis efficacy following local delivery. Nanomedicine (Lond) (2016) 0.75